Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Cavion
Charlottesville, Virginia, United Statescavionpharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Cavion’s lead clinical program, CX‑8998, has been evaluated in the T-CALM trial for essential tremor. The company focuses on modulating the Cav3 channel to address movement disorders and rare epilepsies. As of its acquisition by Jazz Pharmaceuticals in August 2019, it was a clinical-stage company with ongoing trials[1][2].
- Therapeutic areas
- Neurology
- Modalities
- Small molecules (specifically T-type calcium channel modulators)
- Industry
- Biotech
Beyond the preview
Go deeper on Cavion.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cavion.